On average, cancer samples contain 4–5 driver alterations the majority of which are mutations or deletions of tumor suppressor genes (i.e., TP53, BRCA2, APC), and amplifications of oncogenes (i.e., MYC, MCL1, CCND1) [20,21]. This evidence concerns the gene BRCA2 and cancer.